SLC5A2 and atherosclerosis: A recent study by Patorno et al. using real-world data found T2D patients receiving SGLT2 inhibitors had lower risk of hHF, compared to those receiving DPP4 inhibitors, but the magnitudes of the risk differences varied between patients with established ASCVD (44%) and those without established ASCVD (54%) [18].